Date: 2016-09-07
Type of information: Nomination
Compound:
Company: Progenics Pharmaceuticals (USA - NY)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 7, 2016, Progenics Pharmaceuticals, an oncology company developing innovative medicines and other products for targeting and treating cancer, announced the appointment of Bryce V. Tenbarge as Vice President of Commercial, effective August 22, 2016. In this newly created role, Mr. Tenbarge will report to Mark Baker, CEO of Progenics, and will be responsible for leading all of the Company's commercial activities. Mr. Tenbarge brings over fifteen years of experience in biopharmaceutical marketing, most recently as Vice President of Marketing and Commercialization at Celldex Therapeutics.
Mr. Tenbarge joins Progenics from Celldex Therapeutics, where he served as Vice President of Marketing and Commercialization since 2013. From 2012 to 2013, he was Senior Director of Oncology Marketing at Teva Pharmaceuticals. Prior to Teva, he held several marketing positions of increasing responsibility at Bristol-Myers Squibb including Sales, Business Intelligence, Payer and Professional Marketing. Mr. Tenbarge received his MBA from The Ross School of Business at the University of Michigan.
Financial terms:
Latest news:
